User menu

Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.

Bibliographic reference Kass, Rena ; Bellone, Stefania ; Palmieri, Michela ; Cané, Stefania ; Bignotti, Eliana ; et. al. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.. In: Breast Cancer Research and Treatment, Vol. 80, no.3, p. 275-85 (2003)
Permanent URL http://hdl.handle.net/2078.1/138360
  1. Riethmuller G, Johnson JP: Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer. Curr Opin Immunol 4: 647–655, 1992
  2. Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F, Bastert G: Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7: 4102–4108, 2001
  3. Brown DC, Purushotham AD, Birnie GD, GeorgeWD: Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery 117: 96–101, 1995
  4. Braun S, Kentenich C, JanniW, Hepp F, deWaal J, Willgeroth F, Sommer H, Pantel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Oncol 18: 80–86, 2000
  5. Fidler IJ: Modulation of organ environment for treatment of cancer metastases. J Natl Cancer Inst 87: 1588–1592, 1995
  6. Young JW, Inaba K: DC as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183: 7–11, 1996
  7. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186: 1183–1187, 1997
  8. Sallusto F, Lanzavecchia A: Efficient presentation of soluable antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by turner necrosis factor alpha. J Exp Med 17: 1109–1116, 1994
  9. Romani N, Gruner S, Brang D, Kampgen E, Lnez A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–90, 1994
  10. Santin Alessandro D., Hermonat Paul L., Ravaggi Maurizio Chiriva-Internat, Maurizio Chiriva-Internat, Cannon Martin J., Hiserodt John C., Pecorell Sergio, Parham Groesbeck P., Expression of Surface Antigens During the Differentiation of Human Dendritic Cells vs Macrophages from Blood Monocytes in vitro, 10.1016/s0171-2985(99)80069-2
  11. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245–252, 1998
  12. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Pragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135–3142, 1997
  13. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104: 173–180, 1999
  14. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N: Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes. J Clin Invest 105: R9–R14, 2000
  15. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193: 233–238, 2001
  16. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA: Growth of tumorinfiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 65: 13–421, 1996
  17. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM: Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol 156: 3486–3492, 1996
  18. Hudson JM, Castilleja A, Murray JL, Honda T, Kudelka A, Singletary E, Wharton JT, Ioannides CG: Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer. J Interf Cytok Res 18: 529–536, 1998
  19. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neuderived peptide. Proc Natl Acad Sci USA 92: 432–436, 1995
  20. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ: Shared T cell epitopes in epithelial tumors. Cell Immunol 164: 279–286, 1995
  21. Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB: Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 190: 141–155, 1998
  22. Whiteside TL: Tumor infiltrating lymphocytes in human malignancies. Medical Intelligence Unit, R.G. Landes, Austin, TX, 1993
  23. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH: Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived fromrenal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63: 205–212, 1995
  24. Chen YM, Yang WK, Whang-Peng J, Tsai WY, Hung YM, Yang DM, Lin WC, Perng RP, Ting CC: Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J Immunothol 20: 354–364, 1997
  25. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 96: 422–430, 2000
  26. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP: Induction of tumor-specific HLA class I restricted CD8+ cytotoxic T lymphocytes by ovariantumor antigen pulsed autologous dendritic cells in patients with advanced ovarian cancer. Am J Obstet Gynecol 183: 601–609, 2000
  27. Whiteside TL, Miescher S, MacDonald HR, Von Fliedner V: Separation of tumor infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradient. J Immunol Meth 90: 221–233, 1986
  28. Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99: 351–358, 2002
  29. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58, 1996
  30. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332, 1998
  31. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Shuler G: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669–1678, 1999
  32. Kugler A, Stuhler G, Walden P, Zoller G, Zobiwalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert R-H: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332–336, 2000
  33. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61: 8513–8519, 2001
  34. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP: Vaccination with HPV-18 E7-pulsed dendritic cells in a Restoration of tumor-specific HLA class I restricted cytotoxicity 285 patient with metastatic cervical cancer. New Engl J Med 346: 1752–1753, 2002
  35. Fiander A, Adams M, Evans AS, Bennett AJ, Borysiewicz LK: Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients. Int J Gynecol Oncol 5: 438–443, 1995
  36. Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170: 101–110, 1996
  37. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3: 483–490, 1997
  38. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor specific and HLA-A2 restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155: 4486–4491, 1995
  39. Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT, Ioannides CG: Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol Immunol 35: 1121–1133, 1998
  40. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, Ioannides CG: Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 19: 2907–2916, 1999
  41. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97: 2715–2718, 2000
  42. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 319: 1676–1680, 1988
  43. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.J Exp Med 190: 1417–1426, 1999
  44. Liyanage U. K., Moore T. T., Joo H.-G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C., Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma, 10.4049/jimmunol.169.5.2756
  45. Pittet M. J., Speiser D. E., Valmori D., Cerottini J.-C., Romero P., Cutting Edge: Cytolytic Effector Function in Human Circulating CD8+ T Cells Closely Correlates with CD56 Surface Expression, 10.4049/jimmunol.164.3.1148
  46. Romagnani S: Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98: 279-285
  47. Takashi N, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A: Distinct role of antigen-specific T helper Type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190: 617–624, 1999
  48. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87: 1478–1483, 1995
  49. Clerici M, Shearer GM, Clerici F: Cytokine dysregulation in invasive carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst 90: 261–263, 1998